Pharma Mar SA
Ms. de Francia has been with PharmaMar and its predecessor Zeltia since 1988 holding various positions in the finance department, and becoming the Chief Financial Officer of Zeltia in 2000, and then for PharmaMar since the PharmaMar-Zeltia merger in 2015. Ms. de Francia holds an undergraduate degree in law, as well as a graduate degree in Business Administration from the Universidad Pontifical Comillas (ICADE) de Madrid. She also is a member of the Board of Directors for GENOMICA subsidiary.
This person is not in any offices
Pharma Mar SA
Pharma Mar SA is a Spain-based company engaged in the bio therapeutic drugs manufacture. The Company focuses on research, development and marketing of bio-active principles, primarily from marine origin, for application in human diseases treatment, including antitumour, antiviral and immunomodulation, as well as tropical diseases areas. It manufactures and sells Yondelis, a synthetically modified antitumor agent, which is derived from sea squirts and is implemented in the treatment of soft tissue sarcomas and relapsed ovarian cancer. Furthermore, the Company's products pipeline comprises drug candidates and agents for cancer treatment, such as Aplidin, PM01183 and PM060184. The Company operates through subsidiaries in Italy, Germany, France, and the United States, among others.